肾癌增殖细胞核抗原与病理及预后关系的研究  

Research on relationship between PCNA and clinic pathology,prognosis in renal cancer

作　　者：王立忠[1] 刘同才[1] 张铭铮[1] 李书章[1] 任玉鹏[1] 孔垂泽[1] 温强[1] 张辉[1] 

机构地区：[1]中国医科大学第一临床学院泌尿外科,解放军202医院泌尿外科,鞍山钢铁公司长甸医院外科

出　　处：《临床泌尿外科杂志》1996年第1期6-8,共3页Journal of Clinical Urology

摘　　要：为探讨肾癌增殖细胞核抗原（ＰＣＮＡ）与临床病理及预后的关系，采用免疫组织化学Ｓ－Ｐ法对５３例肾癌组织中ＰＣＮＡ进行检测。其中ＰＣＮＡ阳性细胞数和分布呈异质性，ＰＣＮＡ表达与细胞类型、肿瘤分期与分级均相关，ＰＣＮＡ高表达（３～４级）术后５年生存率明显低于低表达（１～２级）。结果表明ＰＣＮＡ可以定量地判定肿瘤分化程度及恶性度，强调ＰＣＮＡ与临床分期结合能更好地判定肾癌的预后，ＰＣＮＡ高表达者易发生转移且预后差，术后应注意复发、转移及加强辅助治疗。Proliferating cell nuclear antigenPCNA)was arrayed by immunohistochemical SP method in 53 cases of renal cancer.The positive cells and distribution of PCNA was heterogenous,PCNA expression corelated with cellular type, phasing and grading, the 5-year survival rate of PCNA higher expression(3～4 grade)was lower than that of lower expressilon rate(1～2 grade)。It was suggested that PCNA could determine the degree of differentiatilon and malignancy of neoplasms quantitively, PCNA connected with clinic phasing can predict the prognosis better. Those with higher PCNA expression metastated easily, and always had bad prognossis.Attention shoud be paid to these patients for recerrence and metastasis, and accessory treatments should be performed.

关 键 词：肾肿瘤 增殖细胞核抗原 免疫组织化学 病理 预后 

分 类 号：R737.110.3[医药卫生—肿瘤]